Stem cell transplant plus CAR-T for aggressive myeloma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests combining a stem cell transplant with a special immune cell therapy (BCMA CAR-T) to treat very aggressive multiple myeloma. The goal is to see if this powerful one-two punch can help people whose myeloma is hard to control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a very aggressive type of multiple myeloma, called ultra-high-risk myeloma.
- You are between 18 and 70 years old.
- Your doctor has said you are healthy enough for a stem cell transplant using your own cells.
- You have not had a stem cell transplant before.
- Your kidneys, liver, heart, and blood counts must be within safe limits for the trial.
- You must not have other serious illnesses like uncontrolled infections, severe heart disease, or certain cancers in the last 3 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a stem cell transplant followed by two targeted therapies — a BCMA CAR-T and a GPRC5D/CD3 bispecific antibody — to treat newly diagnosed multiple myeloma that has ultra-high-risk features. The goal is to see if this combination can better control the disease.
This study combines a stem cell transplant with a special immune therapy (CAR-T) to treat multiple myeloma that is very aggressive and has not responded well to initial treatments. The goal is to see if this combination can better control the cancer.
This trial tests whether a newer immune treatment (BCMA CAR-T) works better than a stem cell transplant for people with multiple myeloma who are able to have a transplant. Both treatments aim to kill myeloma cells, but CAR-T uses your own engineered immune cells.
This trial tests a treatment plan for newly diagnosed plasma cell leukemia that involves a stem cell transplant followed by two types of immunotherapy: CAR-T cells targeting BCMA and a bi-specific antibody targeting GPRC5D. The goal is to see if this approach can help keep the cancer in remission.
This trial tests a new immunotherapy called BCMA CAR-T for people with multiple myeloma that is considered high-risk. It aims to see if this treatment can help patients who had a short response to initial therapy or have specific genetic changes in their cancer.
This trial tests a new immune cell therapy (BCMA-CART) alone or combined with a stem cell transplant for women aged 18-55 with multiple myeloma. It aims to see if this treatment is safe and effective.
Hear when a new Plasma Cell Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.